Literature DB >> 33823801

Genome-scale analyses of transcriptional start sites in Mycobacterium marinum under normoxic and hypoxic conditions.

Shaojia Huang1,2, Wei Zhou1,2, Wei Tang1, Yong Zhang1, Yangbo Hu3, Shiyun Chen4.   

Abstract

BACKGROUND: Hypoxic stress plays a critical role in the persistence of Mycobacterium tuberculosis (Mtb) infection, but the mechanisms underlying this adaptive response remain ill defined.
MATERIAL AND METHODS: In this study, using M. marinum as a surrogate, we analyzed hypoxic responses at the transcriptional level by Cappable-seq and regular RNA-seq analyses.
RESULTS: A total of 6808 transcriptional start sites (TSSs) were identified under normoxic and hypoxic conditions. Among these TSSs, 1112 were upregulated and 1265 were downregulated in response to hypoxic stress. Using SigE-recognized consensus sequence, we identified 59 SigE-dependent promoters and all were upregulated under hypoxic stress, suggesting an important role for SigE in this process. We also compared the performance of Cappable-seq and regular RNA-seq using the same RNA samples collected from normoxic and hypoxic conditions, and confirmed that Cappable-seq is a valuable approach for global transcriptional regulation analyses.
CONCLUSIONS: Our results provide insights and information for further characterization of responses to hypoxia in mycobacteria, and prove that Cappable-seq is a valuable approach for global transcriptional studies in mycobacteria.

Entities:  

Year:  2021        PMID: 33823801     DOI: 10.1186/s12864-021-07572-8

Source DB:  PubMed          Journal:  BMC Genomics        ISSN: 1471-2164            Impact factor:   3.969


  38 in total

Review 1.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

3.  Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.

Authors:  D R Sherman; M Voskuil; D Schnappinger; R Liao; M I Harrell; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

Review 4.  Nonreplicating persistence of mycobacterium tuberculosis.

Authors:  L G Wayne; C D Sohaskey
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

Review 5.  Mycobacterium tuberculosis: success through dormancy.

Authors:  Martin Gengenbacher; Stefan H E Kaufmann
Journal:  FEMS Microbiol Rev       Date:  2012-03-08       Impact factor: 16.408

Review 6.  Hypoxia: a window into Mycobacterium tuberculosis latency.

Authors:  Tige R Rustad; Ashley M Sherrid; Kyle J Minch; David R Sherman
Journal:  Cell Microbiol       Date:  2009-04-15       Impact factor: 3.715

7.  The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages.

Authors:  Y Yuan; D D Crane; R M Simpson; Y Q Zhu; M J Hickey; D R Sherman; C E Barry
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

8.  Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis.

Authors:  Heui-Dong Park; Kristi M Guinn; Maria I Harrell; Reiling Liao; Martin I Voskuil; Martin Tompa; Gary K Schoolnik; David R Sherman
Journal:  Mol Microbiol       Date:  2003-05       Impact factor: 3.501

9.  Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment.

Authors:  Dirk Schnappinger; Sabine Ehrt; Martin I Voskuil; Yang Liu; Joseph A Mangan; Irene M Monahan; Gregory Dolganov; Brad Efron; Philip D Butcher; Carl Nathan; Gary K Schoolnik
Journal:  J Exp Med       Date:  2003-09-01       Impact factor: 14.307

10.  The enduring hypoxic response of Mycobacterium tuberculosis.

Authors:  Tige R Rustad; Maria I Harrell; Reiling Liao; David R Sherman
Journal:  PLoS One       Date:  2008-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.